A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera

Introduction: Ruxolitinib is a small -molecule inhibitor of the JAK1/2 pathway. This study aimed to reveal the results and side-effect profile of the use of ruxolitinib as a treatment option in polycythemia vera (PV). Methods: A total of 34 patients with PV from 18 different centers were included in the study. The evaluation of the response under treatment with ruxolitinib was determined as a reduction in spleen volume (splenomegaly size: ≥35%) by imaging and control of hematocrit levels (≤45%) compared to baseline. Results: While the number of patients in which a reduction in spleen volume and hematocrit control was achieved was 19 (55.9%) at 3 months of treatment, it was 21 (61.8%) at 6 months. Additionally, while the number of side effects was negatively correlated with the reduction in spleen volume (Spearman’s rho: -0.365, p=0.034), a decrease in the hematocrit level was positively correlated (Spearman’s rho: 0.75, p=0.029). Those without a reduction in spleen volume experienced more constipation (chi-square: 5.988, Fisher’s exact test: p=0.033). Conclusion: This study shed light on the use of ruxolitinib in PV and the importance of splenomegaly on studies planned with larger patient groups.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer 2009; 115: 3842-7.
2. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-97.
3. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-61.
4. Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013; 368: 22-33.
5. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350: 114-24.
6. Colafigli G, Scalzulli E, Pepe S, Di Prima A, Efficace F, Martelli M, et al. The advantages and risks of ruxolitinib for the treatment of polycythemia vera. Expert Rev Hematol 2020; 13: 1067-72.
7. Nazha A, Khoury JD, Verstovsek S, Daver N. Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure? Crit Rev Oncol Hematol 2016; 105: 112-7.
8. Alvarez-Larrán A, Pereira A, Cervantes F, Arellano-Rodrigo E, Hernández- Boluda JC, Ferrer-Marín F, et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood 2012; 119: 1363- 9.
9. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29: 761-70.
10. Mascarenhas J, Hoffman R. Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin Cancer Res 2012; 18: 3008-14.
11. Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 2015; 372: 426-35.
12. Passamonti F, Griesshammer M, Palandri F, Egyed M, Benevolo G, Devos T, et al. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol 2017; 18: 88-99.
13. Mesa R, Vannucchi AM, Yacoub A, Zachee P, Garg M, Lyons R, et al. The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). Br J Haematol 2017; 176: 76-85.
14. Coltoff A, Mesa R, Gotlib J, Shulman J, Rampal RK, Siwoski O, et al. Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera. Clin Lymphoma Myeloma Leuk 2020; 20: 697-703.
15. Accurso V, Santoro M, Raso S, Contrino AD, Casimiro P, Piazza FD, et al. Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study. Hematol Rep 2019; 11: 8281.

APA	SERIN I, Doğu M, Ekinci O, Akgun Cagliyan G, BASTURK A, REİS ARAS M, Demircioğlu S, Turgut B, Merter M, Hacioglu S, BAGCI M, ALBAYRAK M, Korkmaz S, ERKURT M, SİNAN DAL M, Ersoy Dursun F, TOMBAK A, AYDOGDU I, Ulas T, Altuntaş F (2023). A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera. , 120 - 125. 10.4274/imj.galenos.2023.66742
Chicago	SERIN Istemi,Doğu Mehmet Hilmi,Ekinci Omer,Akgun Cagliyan Gulsum,BASTURK ABDULKADIR,REİS ARAS MERİH,Demircioğlu Sinan,Turgut Burhan,Merter Mustafa,Hacioglu Sibel,BAGCI METIN,ALBAYRAK MURAT,Korkmaz Serdal,ERKURT MEHMET ALI,SİNAN DAL MEHMET,Ersoy Dursun Fadime,TOMBAK ANIL,AYDOGDU ISMET,Ulas Turgay,Altuntaş Fevzi A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera. (2023): 120 - 125. 10.4274/imj.galenos.2023.66742
MLA	SERIN Istemi,Doğu Mehmet Hilmi,Ekinci Omer,Akgun Cagliyan Gulsum,BASTURK ABDULKADIR,REİS ARAS MERİH,Demircioğlu Sinan,Turgut Burhan,Merter Mustafa,Hacioglu Sibel,BAGCI METIN,ALBAYRAK MURAT,Korkmaz Serdal,ERKURT MEHMET ALI,SİNAN DAL MEHMET,Ersoy Dursun Fadime,TOMBAK ANIL,AYDOGDU ISMET,Ulas Turgay,Altuntaş Fevzi A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera. , 2023, ss.120 - 125. 10.4274/imj.galenos.2023.66742
AMA	SERIN I,Doğu M,Ekinci O,Akgun Cagliyan G,BASTURK A,REİS ARAS M,Demircioğlu S,Turgut B,Merter M,Hacioglu S,BAGCI M,ALBAYRAK M,Korkmaz S,ERKURT M,SİNAN DAL M,Ersoy Dursun F,TOMBAK A,AYDOGDU I,Ulas T,Altuntaş F A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera. . 2023; 120 - 125. 10.4274/imj.galenos.2023.66742
Vancouver	SERIN I,Doğu M,Ekinci O,Akgun Cagliyan G,BASTURK A,REİS ARAS M,Demircioğlu S,Turgut B,Merter M,Hacioglu S,BAGCI M,ALBAYRAK M,Korkmaz S,ERKURT M,SİNAN DAL M,Ersoy Dursun F,TOMBAK A,AYDOGDU I,Ulas T,Altuntaş F A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera. . 2023; 120 - 125. 10.4274/imj.galenos.2023.66742
IEEE	SERIN I,Doğu M,Ekinci O,Akgun Cagliyan G,BASTURK A,REİS ARAS M,Demircioğlu S,Turgut B,Merter M,Hacioglu S,BAGCI M,ALBAYRAK M,Korkmaz S,ERKURT M,SİNAN DAL M,Ersoy Dursun F,TOMBAK A,AYDOGDU I,Ulas T,Altuntaş F "A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera." , ss.120 - 125, 2023. 10.4274/imj.galenos.2023.66742
ISNAD	SERIN, Istemi vd. "A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera". (2023), 120-125. https://doi.org/10.4274/imj.galenos.2023.66742

APA	SERIN I, Doğu M, Ekinci O, Akgun Cagliyan G, BASTURK A, REİS ARAS M, Demircioğlu S, Turgut B, Merter M, Hacioglu S, BAGCI M, ALBAYRAK M, Korkmaz S, ERKURT M, SİNAN DAL M, Ersoy Dursun F, TOMBAK A, AYDOGDU I, Ulas T, Altuntaş F (2023). A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera. İstanbul Medical Journal, 24(2), 120 - 125. 10.4274/imj.galenos.2023.66742
Chicago	SERIN Istemi,Doğu Mehmet Hilmi,Ekinci Omer,Akgun Cagliyan Gulsum,BASTURK ABDULKADIR,REİS ARAS MERİH,Demircioğlu Sinan,Turgut Burhan,Merter Mustafa,Hacioglu Sibel,BAGCI METIN,ALBAYRAK MURAT,Korkmaz Serdal,ERKURT MEHMET ALI,SİNAN DAL MEHMET,Ersoy Dursun Fadime,TOMBAK ANIL,AYDOGDU ISMET,Ulas Turgay,Altuntaş Fevzi A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera. İstanbul Medical Journal 24, no.2 (2023): 120 - 125. 10.4274/imj.galenos.2023.66742
MLA	SERIN Istemi,Doğu Mehmet Hilmi,Ekinci Omer,Akgun Cagliyan Gulsum,BASTURK ABDULKADIR,REİS ARAS MERİH,Demircioğlu Sinan,Turgut Burhan,Merter Mustafa,Hacioglu Sibel,BAGCI METIN,ALBAYRAK MURAT,Korkmaz Serdal,ERKURT MEHMET ALI,SİNAN DAL MEHMET,Ersoy Dursun Fadime,TOMBAK ANIL,AYDOGDU ISMET,Ulas Turgay,Altuntaş Fevzi A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera. İstanbul Medical Journal, vol.24, no.2, 2023, ss.120 - 125. 10.4274/imj.galenos.2023.66742
AMA	SERIN I,Doğu M,Ekinci O,Akgun Cagliyan G,BASTURK A,REİS ARAS M,Demircioğlu S,Turgut B,Merter M,Hacioglu S,BAGCI M,ALBAYRAK M,Korkmaz S,ERKURT M,SİNAN DAL M,Ersoy Dursun F,TOMBAK A,AYDOGDU I,Ulas T,Altuntaş F A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera. İstanbul Medical Journal. 2023; 24(2): 120 - 125. 10.4274/imj.galenos.2023.66742
Vancouver	SERIN I,Doğu M,Ekinci O,Akgun Cagliyan G,BASTURK A,REİS ARAS M,Demircioğlu S,Turgut B,Merter M,Hacioglu S,BAGCI M,ALBAYRAK M,Korkmaz S,ERKURT M,SİNAN DAL M,Ersoy Dursun F,TOMBAK A,AYDOGDU I,Ulas T,Altuntaş F A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera. İstanbul Medical Journal. 2023; 24(2): 120 - 125. 10.4274/imj.galenos.2023.66742
IEEE	SERIN I,Doğu M,Ekinci O,Akgun Cagliyan G,BASTURK A,REİS ARAS M,Demircioğlu S,Turgut B,Merter M,Hacioglu S,BAGCI M,ALBAYRAK M,Korkmaz S,ERKURT M,SİNAN DAL M,Ersoy Dursun F,TOMBAK A,AYDOGDU I,Ulas T,Altuntaş F "A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera." İstanbul Medical Journal, 24, ss.120 - 125, 2023. 10.4274/imj.galenos.2023.66742
ISNAD	SERIN, Istemi vd. "A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera". İstanbul Medical Journal 24/2 (2023), 120-125. https://doi.org/10.4274/imj.galenos.2023.66742